ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Susceptibility of cervical cancer to dihydroartemisinin-induced ferritinophagy-dependent ferroptosis

Shi, Hanqiang; Xiong, Lie; Yan, Guang; Du, Shuqin; Liu, Jie; Shi, Yanbo*南方医科大学; 浙江工业大学
Frontiers in Molecular Biosciences2023-3-31DOI: 10.3389/fmolb.2023.1156062
8被引9阅读
引用收藏
分享

摘要

The clinical therapeutics of cervical cancer is limited due to the drug resistance and metastasis of tumor. As a novel target for antitumor therapy, ferroptosis is deemed to be more susceptible for those cancer cells with resistance to apoptosis and chemotherapy. Dihydroartemisinin (DHA), the primary active metabolites of artemisinin and its derivatives, has exhibited a variety of anticancer properties with low toxicity. However, the role of DHA and ferroptosis in cervical cancer remained unclear. Here, we showed that DHA could time-dependently and dose-dependently inhibit the proliferation of cervical cancer cells, which could be alleviated by the inhibitors of ferroptosis rather than apoptosis. Further investigation confirmed that DHA treatment initiated ferroptosis, as evidenced by the accumulation of reactive oxygen species (ROS), malondialdehyde (MDA) and liquid peroxidation (LPO) levels and simultaneously depletion of glutathione peroxidase 4 (GPX4) and glutathione (GSH). Moreover, nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy was also induced by DHA leading to subsequent increases of intracellular labile iron pool (LIP), exacerbated the Fenton reaction resulting in excessive ROS production, and enhanced cervical cancer ferroptosis. Among them, we unexpectedly found that heme oxygenase-1 (HO-1) played an antioxidant role in DHA-induced cell death. In addition, the results of synergy analysis showed that the combination of DHA and doxorubicin (DOX) emerged a highly synergistic lethal effect for cervical cancer cells, which was related also to ferroptosis. Overall, our data revealed the molecular mechanisms that DHA triggered ferritinophagy-dependent ferroptosis and sensitized to DOX in cervical cancer, which may provide novel avenues for future therapy development.

学科与关键词

关键词
cervical cancerdihydroartemisininferroptosisferritinophagyheme oxygenase-1doxorubicin
相关
加载中…
  • Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment
    Wang, Youke; Yuan, Xiang; Ren, Min*; Wang, Zhiyu*AMERICAN JOURNAL OF CHINESE MEDICINE, 2024.
  • Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy
    Han, Wenbo; Duan, Xiaopin; Ni, Kaiyuan; Li, Youyou; Chan, Christina; Lin, Wenbin*Biomaterials, 2022, 280: 121315.被引 38
  • Dihydroartemisinin eliminates senescent cells by promoting autophagy-dependent ferroptosis via AMPK/mTOR signaling pathway
    Wan, Xing; Li, Can; Tan, Yue Hao; Zuo, Shi Qi; Deng, Feng Mei; Sun, Jing*; Liu, Yi Lun*CELL BIOLOGY INTERNATIONAL, 2024.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Molecular Biosciences
发表日期
2023-03-31
卷期
第 10 卷
页码
1156062
DOI
10.3389/fmolb.2023.1156062
成果收录
SCIE
资助标注
Basic Public Welfare Research Program of Zhejiang Province [LGF18H200004]; Science and Technology Bureau of Jiaxing City [2020AY10002, 2020AY30003]; Scientific Research Project of Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine [2022FSYYZY18]; Jiaxing Key Laboratory of Diabetic Angiopathy [2019ZDSYS]

作者

  • S

    Shi, Hanqiang (第一作者)

    zhejiang chinese med univ

  • X

    Xiong, Lie

    zhejiang chinese med univ

查看全部 6 位作者收起作者
  • Y

    Yan, Guang

    southern med univ

  • D

    Du, Shuqin

    zhejiang chinese med univ · zhejiang univ technol

  • L

    Liu, Jie

    zhejiang chinese med univ

  • S

    Shi, Yanbo (通讯)

    zhejiang chinese med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417